Axsome Therapeutics (NASDAQ:AXSM) Rating Reiterated by HC Wainwright

Axsome Therapeutics (NASDAQ:AXSMGet Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $190.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 158.50% from the company’s current price.

Several other equities research analysts have also weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $108.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday, February 20th. UBS Group assumed coverage on Axsome Therapeutics in a report on Tuesday, February 6th. They set a “buy” rating and a $111.00 price objective for the company. Mizuho increased their price objective on Axsome Therapeutics from $108.00 to $109.00 and gave the stock a “buy” rating in a report on Thursday, March 28th. Guggenheim raised their target price on Axsome Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, February 21st. Finally, Robert W. Baird began coverage on Axsome Therapeutics in a report on Tuesday, March 19th. They set an “outperform” rating and a $108.00 target price on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $119.75.

View Our Latest Stock Report on Axsome Therapeutics

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $73.50 on Tuesday. Axsome Therapeutics has a 12-month low of $55.02 and a 12-month high of $98.40. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.63 and a quick ratio of 3.52. The firm has a market capitalization of $3.48 billion, a price-to-earnings ratio of -14.13 and a beta of 1.13. The business has a 50 day simple moving average of $82.96 and a 200 day simple moving average of $75.24.

Axsome Therapeutics (NASDAQ:AXSMGet Free Report) last posted its earnings results on Tuesday, February 20th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($1.21) by $0.48. Axsome Therapeutics had a negative return on equity of 70.67% and a negative net margin of 88.41%. The firm had revenue of $71.53 million for the quarter, compared to analysts’ expectations of $70.38 million. On average, equities research analysts anticipate that Axsome Therapeutics will post -3.73 EPS for the current year.

Insider Buying and Selling

In related news, COO Mark L. Jacobson sold 24,662 shares of Axsome Therapeutics stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $77.24, for a total transaction of $1,904,892.88. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Axsome Therapeutics news, Director Roger Jeffs sold 29,976 shares of Axsome Therapeutics stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the sale, the director now directly owns 120,756 shares of the company’s stock, valued at $8,416,693.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Mark L. Jacobson sold 24,662 shares of Axsome Therapeutics stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $77.24, for a total value of $1,904,892.88. The disclosure for this sale can be found here. 24.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Trexquant Investment LP acquired a new stake in Axsome Therapeutics during the third quarter valued at approximately $1,220,000. Kennedy Capital Management LLC boosted its holdings in shares of Axsome Therapeutics by 24.2% in the 3rd quarter. Kennedy Capital Management LLC now owns 12,092 shares of the company’s stock worth $845,000 after acquiring an additional 2,354 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Axsome Therapeutics by 18.9% in the 3rd quarter. Wellington Management Group LLP now owns 237,554 shares of the company’s stock worth $16,603,000 after acquiring an additional 37,843 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Axsome Therapeutics by 403.8% in the 3rd quarter. Victory Capital Management Inc. now owns 18,934 shares of the company’s stock worth $1,323,000 after acquiring an additional 15,176 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new position in shares of Axsome Therapeutics in the 3rd quarter worth approximately $10,427,000. 81.49% of the stock is owned by institutional investors and hedge funds.

About Axsome Therapeutics

(Get Free Report)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

Recommended Stories

Analyst Recommendations for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.